Home > Insider Trading > Filing (0001104659-21-117993)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1817944	Clarus Therapeutics Holdings Inc.	CRXT	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1081816	Ltd Fund Ffi	C/O Bracebridge Capital, Llc 888 Boylston Street, 15Th Floor Boston MA 02199	No	No	Yes	No
1411786	Ltd Fyi	C/O Bracebridge Capital, Llc 888 Boylston Street, 15Th Floor Boston MA 02199	No	No	Yes	No
1426486	Bracebridge Capital, Llc	888 Boylston Street, 15Th Floor Boston MA 02199	No	No	Yes	No
1639809	Olifant Fund, Ltd.	C/O Bracebridge Capital, Llc 888 Boylston Street, 15Th Floor Boston MA 02199	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-09-17	127,360	$9.20	2,102,495	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote

Footnotes

Shares of common stock, $0.0001 par value per share ("Shares") of Clarus Therapeutics Holdings, Inc. (the "Issuer"), were sold as follows: (i) 92,973 Shares were sold by FFI Fund Ltd. ("FFI"), (ii) 17,830 Shares were sold by FYI Ltd. ("FYI"), and (iii) 16,557 Shares were sold by Olifant Fund, Ltd. (together with FFI and FYI, the "Bracebridge Funds"). Bracebridge Capital, LLC (the "Investment Manager") is the investment manager of each of the Bracebridge Funds and has the authority to vote and dispose of all the Shares reflected herein.
This price is a weighted-average price. These Shares were sold in multiple transactions at prices ranging from $9.05 to $9.34, inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares sold at each separate price within the ranges set forth in this explanatory note.
Each of the Bracebridge Funds and the Investment Manager disclaims beneficial ownership of the Shares except to the extent of any pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the Shares reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.